Last reviewed · How we verify
NCT05602337
A Prospective Multicenter Sample Collection Study Using Non-invasive Methods to Investigate Mutation Burden in Non-lesional Facial Skin of Patients With a Hx of Skin Cancer
trial testing Observational Study Only in Melanoma and Other Malignant Neoplasms of Skin in 180 participants. Status unknown.
15 November 2024
Quick facts
| Lead sponsor | DermTech |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 180 |
| Start date | 15 November 2022 |
| Primary completion | 15 November 2024 |
| Estimated completion | 15 March 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Observational Study Only
Conditions studied
- Melanoma and Other Malignant Neoplasms of Skin — all drugs for Melanoma and Other Malignant Neoplasms of Skin →
Sponsor
DermTech — full company profile →
Who can join
Adults 18 to 70, any sex, with Melanoma and Other Malignant Neoplasms of Skin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, multicenter, sample collection study using DermTech's non-invasive skin collection kits to evaluate the mutation burden of non-lesional facial skin from subjects with a documented history of numerous basal cell carcinomas, squamous cell carcinomas or melanomas compared to that of subjects with no history of skin cancer matched for age, sex and Fitzpatrick phototype.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05602337
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melanoma and Other Malignant Neoplasms of Skin
Currently open trials in the same condition.
- NCT07072143 — An International Study on Pediatric Patients With Rare Tumors. · recruiting
- NCT03093909 — Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases · Phase 1 · recruiting
- NCT03131908 — Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Mela · Phase 1, PHASE2 · active not recruiting
Other DermTech trials
Trials by the same sponsor.
- NCT04699695 — A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients · unknown
- NCT05079737 — Sample Collection Study to Assess Prevalence of Gene Mutations: Establishing Population Norms · unknown
- NCT04668846 — A Sample Collection Study Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits · unknown
- NCT04550000 — Sample Collection Study in Patients With Suspected Melanoma Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits · completed
- NCT04563949 — DermTech's Non-Invasive Pigmented Lesion Assay to Detect and Track Lesions for Suspected Melanoma and to Determine Outco · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05602337 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by DermTech
- Last refreshed: 2 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05602337.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing